Valeo Pharma Inc. Logo

Valeo Pharma Inc.

VPHIF

(2.2)
Stock Price

0,05 USD

-149.2% ROA

62.6% ROE

-0.2x PER

Market Cap.

6.320.336,53 USD

-111.18% DER

0% Yield

-60.18% NPM

Valeo Pharma Inc. Stock Analysis

Valeo Pharma Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Valeo Pharma Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (142%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.55x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-215%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 ROA

The stock's ROA (-81.11%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Valeo Pharma Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Valeo Pharma Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Valeo Pharma Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Valeo Pharma Inc. Revenue
Year Revenue Growth
2016 985.705
2017 1.277.489 22.84%
2018 4.381.681 70.84%
2019 6.577.000 33.38%
2020 7.470.000 11.95%
2021 13.557.000 44.9%
2022 27.745.000 51.14%
2023 56.328.000 50.74%
2023 53.910.000 -4.49%
2024 50.404.000 -6.96%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Valeo Pharma Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 126.263 100%
2018 0 0%
2019 8.000 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Valeo Pharma Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 1.095.406
2017 2.844.793 61.49%
2018 2.980.311 4.55%
2019 3.041.000 2%
2020 3.324.000 8.51%
2021 13.306.000 75.02%
2022 18.811.000 29.26%
2023 21.712.000 13.36%
2023 22.562.000 3.77%
2024 21.544.000 -4.73%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Valeo Pharma Inc. EBITDA
Year EBITDA Growth
2016 -2.338.460
2017 -2.552.545 8.39%
2018 -2.328.145 -9.64%
2019 -3.410.000 31.73%
2020 -3.693.000 7.66%
2021 -11.858.000 68.86%
2022 -17.558.000 32.46%
2023 -11.108.000 -58.07%
2023 -10.880.000 -2.1%
2024 -10.332.000 -5.3%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Valeo Pharma Inc. Gross Profit
Year Gross Profit Growth
2016 -1.366.959
2017 530.402 357.72%
2018 832.967 36.32%
2019 1.401.000 40.54%
2020 1.381.000 -1.45%
2021 3.955.000 65.08%
2022 6.281.000 37.03%
2023 17.080.000 63.23%
2023 13.077.000 -30.61%
2024 12.136.000 -7.75%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Valeo Pharma Inc. Net Profit
Year Net Profit Growth
2016 -1.276.490
2017 -3.618.785 64.73%
2018 -2.436.963 -48.5%
2019 -3.615.000 32.59%
2020 -4.761.000 24.07%
2021 -14.233.000 66.55%
2022 -25.746.000 44.72%
2023 -23.352.000 -10.25%
2023 -27.808.000 16.02%
2024 -32.768.000 15.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Valeo Pharma Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Valeo Pharma Inc. Free Cashflow
Year Free Cashflow Growth
2016 -2.457.486
2017 -2.487.007 1.19%
2018 -1.656.663 -50.12%
2019 -3.252.000 49.06%
2020 -6.703.000 51.48%
2021 -15.780.000 57.52%
2022 -35.394.000 55.42%
2023 -1.370.000 -2483.5%
2023 -21.248.000 93.55%
2024 451.000 4811.31%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Valeo Pharma Inc. Operating Cashflow
Year Operating Cashflow Growth
2016 -1.979.477
2017 -1.231.564 -60.73%
2018 -1.333.449 7.64%
2019 -2.307.000 42.2%
2020 -5.298.000 56.46%
2021 -12.315.000 56.98%
2022 -28.503.000 56.79%
2023 -1.259.000 -2163.94%
2023 -15.695.000 91.98%
2024 451.000 3580.04%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Valeo Pharma Inc. Capital Expenditure
Year Capital Expenditure Growth
2016 478.009
2017 1.255.443 61.93%
2018 323.214 -288.42%
2019 945.000 65.8%
2020 1.405.000 32.74%
2021 3.465.000 59.45%
2022 6.891.000 49.72%
2023 111.000 -6108.11%
2023 5.553.000 98%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Valeo Pharma Inc. Equity
Year Equity Growth
2016 955.748
2017 -2.602.534 136.72%
2018 -1.367.506 -90.31%
2019 -22.000 -6115.94%
2020 3.069.000 100.72%
2021 2.053.000 -49.49%
2022 -17.848.000 111.5%
2023 -40.337.000 55.75%
2023 -35.046.000 -15.1%
2024 -63.034.000 44.4%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Valeo Pharma Inc. Assets
Year Assets Growth
2016 4.260.026
2017 3.399.699 -25.31%
2018 3.385.465 -0.42%
2019 5.807.000 41.7%
2020 10.963.000 47.03%
2021 21.030.000 47.87%
2022 58.265.000 63.91%
2023 41.207.000 -41.4%
2023 45.537.000 9.51%
2024 32.195.000 -41.44%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Valeo Pharma Inc. Liabilities
Year Liabilities Growth
2016 3.304.278
2017 6.002.233 44.95%
2018 4.752.971 -26.28%
2019 5.829.000 18.46%
2020 7.894.000 26.16%
2021 18.977.000 58.4%
2022 76.113.000 75.07%
2023 81.544.000 6.66%
2023 80.583.000 -1.19%
2024 95.229.000 15.38%

Valeo Pharma Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.54
Net Income per Share
-0.33
Price to Earning Ratio
-0.2x
Price To Sales Ratio
0.12x
POCF Ratio
-1.48
PFCF Ratio
-0.67
Price to Book Ratio
-0.1
EV to Sales
1.3
EV Over EBITDA
-5.4
EV to Operating CashFlow
-16.19
EV to FreeCashFlow
-7.37
Earnings Yield
-5.08
FreeCashFlow Yield
-1.49
Market Cap
0,01 Bil.
Enterprise Value
0,07 Bil.
Graham Number
2.16
Graham NetNet
-0.83

Income Statement Metrics

Net Income per Share
-0.33
Income Quality
0.13
ROE
0.63
Return On Assets
-1
Return On Capital Employed
0.51
Net Income per EBT
1
EBT Per Ebit
1.68
Ebit per Revenue
-0.36
Effective Tax Rate
-0.14

Margins

Sales, General, & Administrative to Revenue
0.4
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.17
Operating Profit Margin
-0.36
Pretax Profit Margin
-0.6
Net Profit Margin
-0.6

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.1
Capex to Operating CashFlow
-1.2
Capex to Revenue
0.1
Capex to Depreciation
1.92
Return on Invested Capital
-3.41
Return on Tangible Assets
-1.49
Days Sales Outstanding
32.65
Days Payables Outstanding
82.08
Days of Inventory on Hand
40.17
Receivables Turnover
11.18
Payables Turnover
4.45
Inventory Turnover
9.09
Capex per Share
0.05

Balance Sheet

Cash per Share
0,07
Book Value per Share
-0,64
Tangible Book Value per Share
-0.75
Shareholders Equity per Share
-0.64
Interest Debt per Share
0.86
Debt to Equity
-1.11
Debt to Assets
2.18
Net Debt to EBITDA
-4.91
Current Ratio
0.27
Tangible Asset Value
-0,07 Bil.
Net Current Asset Value
-0,08 Bil.
Invested Capital
-37719000
Working Capital
-0,05 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,01 Bil.
Average Payables
0,01 Bil.
Average Inventory
5771500
Debt to Market Cap
11.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Valeo Pharma Inc. Dividends
Year Dividends Growth

Valeo Pharma Inc. Profile

About Valeo Pharma Inc.

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.

CEO
Mr. Al Moghaddam B. Com. Cma
Employee
70
Address
16667 Hymus Boulevard
Kirkland, H9H 4R9

Valeo Pharma Inc. Executives & BODs

Valeo Pharma Inc. Executives & BODs
# Name Age
1 Mr. Al Moghaddam B. Com. Cma
Chief Executive Officer
70
2 Mr. Frédéric Dumais
Director of Communications & Investor Relations
70
3 Mr. Kyle Steiger
Senior Vice President & Chief Commercial Officer
70
4 Mr. Pascal Tougas
Chief Financial Officer
70
5 Mr. Guy-Paul Allard
Vice President of Legal Affairs & Corporate Secretary
70
6 Mr. Jean Francois Fournier
Head of Ophthalmology Business Unit
70

Valeo Pharma Inc. Competitors